Type 1 diabetes: benefits of intensive insulin therapy. Patients should control blood glucose strictly.
The DCCT randomised trial compared insulin therapy with strict glycaemic control versus less strict insulin therapy in patients with type 1 diabetes. The trial itself lasted more than 6 years, and most of the patients were subsequently followed up for another 4 years. The initial benefit of strict glycaemic control on the onset or worsening of diabetic retinopathy and nephropathy does appear to persist in the long term
D001786:Blood Glucose / Q000378:metabolism; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use*; D016896:Treatment Outcome
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin